HC Wainwright Reiterates Buy Rating for Evolus (NASDAQ:EOLS)

Evolus (NASDAQ:EOLS)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They presently have a $27.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 100.30% from the company’s previous close.

Separately, Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Tuesday.

Evolus Price Performance

Shares of NASDAQ:EOLS opened at $13.48 on Wednesday. The company’s fifty day moving average is $11.67 and its two-hundred day moving average is $13.74. The company has a market cap of $853.55 million, a P/E ratio of -14.81 and a beta of 1.32. Evolus has a 12-month low of $9.25 and a 12-month high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Essex Investment Management Co. LLC raised its stake in shares of Evolus by 0.4% during the 3rd quarter. Essex Investment Management Co. LLC now owns 295,553 shares of the company’s stock worth $4,788,000 after purchasing an additional 1,111 shares in the last quarter. Creative Planning increased its holdings in Evolus by 23.7% in the third quarter. Creative Planning now owns 15,451 shares of the company’s stock worth $250,000 after buying an additional 2,963 shares during the last quarter. Sei Investments Co. raised its position in Evolus by 9.8% during the second quarter. Sei Investments Co. now owns 33,802 shares of the company’s stock valued at $367,000 after acquiring an additional 3,020 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Evolus by 65.0% in the third quarter. China Universal Asset Management Co. Ltd. now owns 12,135 shares of the company’s stock valued at $197,000 after acquiring an additional 4,780 shares during the last quarter. Finally, Quarry LP bought a new stake in Evolus in the second quarter worth approximately $54,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.